公开(公告)号：EP1311248B1

公开(公告)日：2007-05-02

申请号：EP01978305.9

申请日：2001-08-24

申请人： Axxonis Pharma AG

发明人： HOROWSKI, Reinhard ,  TACK, Johannes ,  ENGFER, Adalbert

IPC分类号： A61K9/70 ,  A61K31/48 ,  A61P25/14 ,  A61P5/08 ,  A61P5/24

CPC分类号： A61K9/7061 ,  A61K31/48

摘要： The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and /or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the restless-legs-syndrome.

公开(公告)号：EP2083008A1

公开(公告)日：2009-07-29

申请号：EP09159841.7

申请日：2007-12-07

申请人： Axxonis Pharma AG

发明人： Flieger, Miroslav ,  Kranda, Karel ,  Latté, Klaus Peter ,  Pertz, Heinz ,  Horowski, Reinhard

IPC分类号： C07D457/06 ,  A61K31/48 ,  C07D457/04

CPC分类号： C07D457/00 ,  C07D457/02 ,  C07D457/04 ,  C07D457/06 ,  C07D457/12

摘要： The present invention relates to new Ergot alkaloid derivatives of the general formula (I) or pharmaceutically acceptable salts thereof as well as to the use of specific compounds as selective radical scavengers for neurons.

摘要翻译： 本发明涉及通式（I）的新的Ergot生物碱衍生物或其药学上可接受的盐，以及特定化合物作为神经元的选择性自由基清除剂的用途。

公开(公告)号：EP2079458A2

公开(公告)日：2009-07-22

申请号：EP07802907.1

申请日：2007-08-27

申请人： Axxonis Pharma AG

发明人： TACK, Johannes ,  SCHURAD, Björn ,  MÜLLER-SCHUBERT, Antje ,  HOROWSKI, Reinhard

IPC分类号： A61K9/70 ,  A61K47/06 ,  A61K47/10 ,  A61K47/32 ,  A61K47/44 ,  C07D457/00 ,  A61K47/16

CPC分类号： A61K9/7061 ,  A61K31/48

摘要： The present invention relates to a transdermal therapeutic system (TTS) comprising an impermeable covering layer, a matrix containing an ergolin compound of formula (I) or the physiologically compatible salt or derivative thereof, wherein R1 represents an H atom or a halogen atom and R2 an alkyl group with 1 to 4 carbon atoms and ------ a single or double bond, and a removable protective layer, the ergolin compound or the physiologically compatible salt or derivative thereof being stabilized by an antioxidant and a basic polymer. The TTS is characterized in that the matrix contains at least one hydrocarbon having 8 to 18 carbon atoms in a linear or branched chain and carrying a functional group at the end of the alkyl chain, and/or aloe vera oil so that, in a first phase (0-5 hours after application), only 0 to 20 % of the therapeutically desired steady state plasma concentration of the ergolin compound is achieved and, in a second phase (5-20 hours after application), the therapeutically desired steady state plasma concentration of the ergolin compound is achieved.

公开(公告)号：EP1303278B1

公开(公告)日：2008-11-05

申请号：EP01976150.1

申请日：2001-08-24

申请人： Axxonis Pharma AG

发明人： HOROWSKI, Reinhard ,  TACK, Johannes

IPC分类号： A61K31/48 ,  A61P25/14 ,  A61P25/16 ,  A61K31/45 ,  A61K31/13 ,  A61K9/00 ,  A61K9/20 ,  A61K9/70

CPC分类号： A61K9/7061 ,  A61K31/48

摘要： The invention relates to the use of a dopamine agonist in the form of an agent, comprising at least two physically separate compositions, of which one is a transdermal therapeutic system (TTS), containing the dopaminergic agent and one or several other compositions containing the same dopaminergic agent and suitable for oral and/or parenteral administration. Said compositions are suitable for the individually dosed and controlled treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.

公开(公告)号：EP1660054B1

公开(公告)日：2008-08-13

申请号：EP04735452.7

申请日：2004-05-30

申请人： Axxonis Pharma AG

发明人： HOROWSKI, Reinhard ,  TACK, Johannes ,  BOSTEDT, Katalin Tisa ,  SCHENK, Dirk

IPC分类号： A61K9/70

CPC分类号： A61K9/7061 ,  A61K31/48 ,  A61K47/10

摘要： The invention relates to a transdermal, therapeutic system containing an ergolin compound, preferably lisuride, in which the ergolin compound is stabilised. The oxidation-sensitive ergolin compound is stabilised by a combination of at least one liposoluble, free-radical scavenging anti-oxidant, preferably di-tert.-butyl methyl phenol, di-tert.-butyl methoxyphenol, tocopherol or ubiquinone and a basic polymer.

公开(公告)号：EP1311249B1

公开(公告)日：2009-10-07

申请号：EP01978306.7

申请日：2001-08-24

申请人： Axxonis Pharma AG

发明人： WINDT-HANKE, Fred ,  GÜNTHER, Clemens ,  HOROWSKI, Reinhard ,  TACK, Johannes

IPC分类号： A61K9/70 ,  A61K31/48 ,  A61P5/08 ,  A61P5/24

CPC分类号： A61K9/7061 ,  A61K31/48

摘要： The invention relates to a use of a transdermal therapeutic system (TTS) for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. Said system comprises a pharmaceutical layer containing at least one matrix having an active ingredient; and/or an active ingredient reservoir; a diffusion barrier which is permeable to active ingredients and which is arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof having a physiologically compatible acid, as an active ingredient.

公开(公告)号：EP2067780A1

公开(公告)日：2009-06-10

申请号：EP07122627.8

申请日：2007-12-07

申请人： Axxonis Pharma AG

发明人： Flieger, Miroslav ,  Kranda, Karel ,  Latté, Klaus Peter ,  Pertz, Heinz H. ,  Horowski, Reinhard

IPC分类号： C07D457/00 ,  C07D457/02 ,  C07D457/06 ,  C07D457/12 ,  A61K31/48 ,  C07D457/04

CPC分类号： C07D457/00 ,  C07D457/02 ,  C07D457/04 ,  C07D457/06 ,  C07D457/12

摘要： The present invention relates to new Ergot alkaloid derivatives of the general formula (I) or pharmaceutically acceptable salts thereof as well as to the use of specific compounds as selective radical scavengers for neurons.

摘要翻译： 本发明涉及通式（I）的新麦角生物碱衍生物或其药学上可接受的盐，以及特定化合物作为神经元选择性自由基清除剂的用途。

公开(公告)号：EP1972333A1

公开(公告)日：2008-09-24

申请号：EP08102111.5

申请日：2008-02-28

申请人： Axxonis Pharma AG

发明人： Schurad, Björn ,  Mottl, Harald

IPC分类号： A61K9/00 ,  A61K31/48 ,  A61K47/10

CPC分类号： A61K9/0019 ,  A61K31/48 ,  A61K47/10

摘要： Die vorliegende Erfindung betrifft stabilisierte wässrige Lösungen einer Ergolinverbindung der Formel I,

oder deren physiologisch verträglichem Salz oder Derivat, wobei R 1 ein H-Atom oder ein Halogenatom und R 2 eine Alkyl- oder Alkenylgruppe mit 1 bis 4 Kohlenstoffatomen undeine Einfach- oder Doppelbindung bedeutet, welche weiterhin 0.05 bis 90.00% mindestens eines sauerstoffhaltigen Cosolvenz enthalten. Ebenso betrifft die vorliegende Erfindung die Verwendung der erfindungsgemäß stabilisierten Lösungen zur Herstellung eines Mittels für die parenterale Behandlung von neurodegenerativen Erkrankungen oder Schädigungen des Gehirns.

摘要翻译： 麦角灵化合物（I）的水溶液含有0.05-90w / v％的含氧助溶剂。 式（I）的麦角灵化合物，其盐或衍生物的水溶液含有0.05-90w / v％的含氧助溶剂。 R 1> H或卤素; R 2> 1-4C烷基或烯基。 活动：神经保护; 脑保护; 抗帕金森病。 行动机制：无给予。